ArticleOncotarget2016

Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.

Yang Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.